Xencor And Roche Extend XmAb Antibody Therapeutics Collaboration

MONROVIA, Calif.--(BUSINESS WIRE)--Jan. 4, 2006 - Xencor, Inc., a biotherapeutics company developing protein and antibody therapeutics, today announced an extension to its research collaboration with Roche to create monoclonal antibodies with differentiated pharmacological profiles. Roche and Xencor entered into an initial collaboration in January 2005, in which Roche applies Xencor's XmAb Fc domains with the aim of enhancing the therapeutic efficacy of an antibody against a cancer target. With this extension, Roche can further its research efforts against such target.